Open access
Open access
Powered by Google Translator Translator

Review: COVID-19-associated coagulopathy and antithrombotic agents – In non-critically ill hospitalized patients, therapeutic dose anticoagulation may improve clinical outcomes. In critically ill patients, this same treatment does not improve outcomes, and prophylactic dose anticoagulation is recommended

29 Apr, 2021 | 08:46h | UTC

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year – The Lancet Haematology

Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.